Literature DB >> 31264691

How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?

David M Margolis1, Steven G Deeks2.   

Abstract

In this discussion, 2 established researchers and clinical trialists debate their opposing views on the utility, benefits, and risks of the use of analytical interruption of antiretroviral therapy as a clinical trial end point and outcome measure in human studies seeking to induce remission of or eradicate human immunodeficiency virus infection.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Analytical treatment interruption; antiretroviral therapy; viral outgrowth assay

Mesh：

Substances：

Year:  2019        PMID： 31264691      PMCID： PMC6636248          DOI： 10.1093/infdis/jiz222

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs.

Authors:  J S Murray; M R Elashoff; L C Iacono-Connors; T A Cvetkovich; K A Struble
Journal:  AIDS       Date:  1999-05-07       Impact factor: 4.177

2.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

3.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Authors:  Amanda M Crooks; Rosalie Bateson; Anna B Cope; Noelle P Dahl; Morgan K Griggs; JoAnn D Kuruc; Cynthia L Gay; Joseph J Eron; David M Margolis; Ronald J Bosch; Nancie M Archin
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

4.  Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Feng Fu; Martin A Nowak; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-05       Impact factor: 11.205

5.  Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay.

Authors:  Gregory M Laird; Daniel I S Rosenbloom; Jun Lai; Robert F Siliciano; Janet D Siliciano
Journal:  Methods Mol Biol       Date:  2016

6.  Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.

Authors:  Timothy J Henrich; Emily Hanhauser; Francisco M Marty; Michael N Sirignano; Sheila Keating; Tzong-Hae Lee; Yvonne P Robles; Benjamin T Davis; Jonathan Z Li; Andrea Heisey; Alison L Hill; Michael P Busch; Philippe Armand; Robert J Soiffer; Marcus Altfeld; Daniel R Kuritzkes
Journal:  Ann Intern Med       Date:  2014-09-02       Impact factor: 25.391

7.  Absence of detectable HIV-1 viremia after treatment cessation in an infant.

Authors:  Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga
Journal:  N Engl J Med       Date:  2013-10-23       Impact factor: 91.245

8.  Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.

Authors:  Trevor A Crowell; Kelly A Gebo; Joel N Blankson; P Todd Korthuis; Baligh R Yehia; Richard M Rutstein; Richard D Moore; Victoria Sharp; Ank E Nijhawan; W Christopher Mathews; Lawrence H Hanau; Roberto B Corales; Robert Beil; Charurut Somboonwit; Howard Edelstein; Sara L Allen; Stephen A Berry
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

9.  Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.

Authors:  Asier Sáez-Cirión; Charline Bacchus; Laurent Hocqueloux; Véronique Avettand-Fenoel; Isabelle Girault; Camille Lecuroux; Valerie Potard; Pierre Versmisse; Adeline Melard; Thierry Prazuck; Benjamin Descours; Julien Guergnon; Jean-Paul Viard; Faroudy Boufassa; Olivier Lambotte; Cécile Goujard; Laurence Meyer; Dominique Costagliola; Alain Venet; Gianfranco Pancino; Brigitte Autran; Christine Rouzioux
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

10.  Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4.

Authors:  Sophie Grabar; Hana Selinger-Leneman; Sophie Abgrall; Gilles Pialoux; Laurence Weiss; Dominique Costagliola
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240
View more
  10 in total

1.  Predictors of SIV recrudescence following antiretroviral treatment interruption.

Authors:  Mykola Pinkevych; Christine M Fennessey; Deborah Cromer; Carolyn Reid; Charles M Trubey; Jeffrey D Lifson; Brandon F Keele; Miles P Davenport
Journal:  Elife       Date:  2019-10-25       Impact factor: 8.140

2.  Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.

Authors:  Karen L Diepstra; Liz Barr; David Palm; Evelyn Hogg; Katie R Mollan; Laney Henley; Angela M Stover; Jane M Simoni; Jeremy Sugarman; Brandon Brown; John A Sauceda; Steven Deeks; Lawrence Fox; Rajesh T Gandhi; Davey Smith; Jonathan Z Li; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2021-02-16       Impact factor: 1.723

3.  Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.

Authors:  Karine Dubé; Shadi Eskaf; Liz Barr; David Palm; Evelyn Hogg; Jane M Simoni; Jeremy Sugarman; Brandon Brown; John A Sauceda; Laney Henley; Steven Deeks; Lawrence Fox; Rajesh T Gandhi; Davey Smith; Jonathan Z Li
Journal:  AIDS Res Hum Retroviruses       Date:  2022-04-21       Impact factor: 1.723

Review 4.  Novel Approaches Towards a Functional Cure of HIV/AIDS.

Authors:  Lucia Bailon; Beatriz Mothe; Lance Berman; Christian Brander
Journal:  Drugs       Date:  2020-06       Impact factor: 9.546

5.  Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research.

Authors:  Evelyn Y Bonney; Helena Lamptey; James O Aboagye; Christopher Zaab-Yen Abana; Anthony T Boateng; Darius N K Quansah; Adjoa Obo-Akwa; Vincent J Ganu; Peter Puplampu; George B Kyei
Journal:  J Virus Erad       Date:  2021-01-01

6.  Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.

Authors:  Adam Gilbertson; Joseph D Tucker; Karine Dubé; Maartje Dijkstra; Stuart Rennie
Journal:  BMC Med Ethics       Date:  2021-12-28       Impact factor: 2.652

7.  Prolonged viral suppression with anti-HIV-1 antibody therapy.

Authors:  Marina Caskey; Michel C Nussenzweig; Christian Gaebler; Lilian Nogueira; Elina Stoffel; Thiago Y Oliveira; Gaëlle Breton; Katrina G Millard; Martina Turroja; Allison Butler; Victor Ramos; Michael S Seaman; Jacqueline D Reeves; Christos J Petroupoulos; Irina Shimeliovich; Anna Gazumyan; Caroline S Jiang; Nikolaus Jilg; Johannes F Scheid; Rajesh Gandhi; Bruce D Walker; Michael C Sneller; Anthony Fauci; Tae-Wook Chun
Journal:  Nature       Date:  2022-04-13       Impact factor: 69.504

8.  Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir.

Authors:  Taina T Immonen; Christine M Fennessey; Leslie Lipkey; Abigail Thorpe; Gregory Q Del Prete; Jeffrey D Lifson; Miles P Davenport; Brandon F Keele
Journal:  PLoS Pathog       Date:  2021-06-18       Impact factor: 6.823

9.  A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption.

Authors:  Michael J Peluso; Lynda Dee; Danielle Campbell; Jeff Taylor; Rebecca Hoh; Rachel L Rutishauser; John Sauceda; Steven G Deeks; Karine Dubé
Journal:  J Virus Erad       Date:  2020-02-20

10.  Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.

Authors:  Jillian S Y Lau; Deborah Cromer; Mykola Pinkevych; Sharon R Lewin; Thomas A Rasmussen; James H McMahon; Miles P Davenport
Journal:  J Infect Dis       Date:  2022-08-24       Impact factor: 7.759
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.